Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc. (NASDAQ: INVA), said XACDURO, ZEVTERA and NUZOLVENCE have been designated finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award. The three FDA-approved antibacterial therapies address markedly different infectious disease settings, ranging from hospital-acquired pneumonia caused by susceptible Acinetobacter bacteria to Staphylococcus aureus bloodstream infections and uncomplicated urogenital gonorrhea.
The announcement is an industry recognition rather than new clinical evidence, a regulatory decision or an expansion of any product label. Its significance instead lies in the concentration of three relatively recent antimicrobial products within one commercial platform at a time when developing and successfully commercializing new antibiotics remains difficult. The Galien Foundation says its pharmaceutical category considers products approved by the FDA within the preceding five years, with the 2026 winners scheduled to be announced on October 29 in New York.
The three therapies are also at different points in their commercial lives. XACDURO is already producing identifiable product revenue for Innoviva, while ZEVTERA has been commercially available in the United States since 2025. NUZOLVENCE received FDA approval in December 2025, but Innoviva’s latest financial disclosures indicated that patient availability remained planned for the second half of 2026.
Why does having three Prix Galien finalists matter for Innoviva’s anti-infective strategy?
The most notable element is not simply that Innoviva has three candidates for the same award. It is that the products cover different pathogens, treatment settings and routes of administration, giving Innoviva Specialty Therapeutics a broader infectious disease platform than a single-product antibiotic company would possess. XACDURO is a targeted intravenous therapy for a difficult hospital pneumonia setting, ZEVTERA gives the company exposure to several serious bacterial infections including Staphylococcus aureus bacteremia, and NUZOLVENCE brings a single-dose oral therapy into the sexually transmitted infection market.
That diversification matters commercially because antibiotic markets are rarely interchangeable. Hospital formulary decisions, infectious disease stewardship programs, susceptibility patterns, reimbursement arrangements and diagnostic confirmation can all influence how frequently a particular antimicrobial is used. A therapy intended for resistant Acinetobacter pneumonia therefore faces a very different adoption pathway from an oral treatment for uncomplicated gonorrhea.
Innoviva’s recent financial performance also suggests that its specialty therapeutics operation is becoming a more meaningful part of the broader business. In the second quarter of 2026, Innoviva reported net product sales of $51.8 million, up 46% from the corresponding period a year earlier. United States product sales reached $36.6 million, while management maintained its expectation of at least $150 million in United States net product sales from Innoviva Specialty Therapeutics during 2026.
The Prix Galien nominations do not prove that this commercial trajectory will continue, but they arrive as Innoviva shifts from assembling an anti-infective portfolio toward demonstrating whether multiple differentiated products can gain sustained clinical and commercial use.
What is driving XACDURO’s position in difficult Acinetobacter hospital pneumonia?
The FDA approved XACDURO, a combination of sulbactam and durlobactam, in May 2023 for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex. Importantly, the label is pathogen-specific. XACDURO is not indicated for hospital-acquired or ventilator-associated pneumonia caused by other organisms.
That narrow indication is commercially important to understand. XACDURO is not attempting to become a general hospital pneumonia antibiotic. Its role is concentrated in a difficult infection where antimicrobial resistance and treatment limitations can make therapeutic selection particularly challenging.
The product has now moved well beyond regulatory approval into measurable commercialization. Innoviva reported $12.0 million of United States XACDURO net product sales in the second quarter of 2026, compared with $11.6 million in the first quarter. The company has also extended the product’s geographic strategy, including a second-quarter agreement with Dr. Reddy’s Laboratories covering development and commercialization across specified markets in South and Central America, the Caribbean, Russia and Commonwealth of Independent States countries.
For XACDURO, therefore, the more relevant question after the Prix Galien recognition is whether sales can continue building while appropriate antimicrobial stewardship keeps use concentrated in patients whose infections fit the label and susceptibility profile.
How does ZEVTERA broaden Innoviva’s reach across serious bacterial infections?
ZEVTERA, or ceftobiprole medocaril sodium for injection, received FDA approval in April 2024 across three indications. These comprise Staphylococcus aureus bloodstream infections in adults, including right-sided infective endocarditis, acute bacterial skin and skin structure infections in adults, and community-acquired bacterial pneumonia in adults and pediatric patients aged three months to less than 18 years.
Its Staphylococcus aureus bacteremia indication gives ZEVTERA particular strategic relevance within a hospital anti-infective portfolio. In the Phase 3 ERADICATE trial supporting that part of the program, ceftobiprole was evaluated against daptomycin, with or without aztreonam, and met the study’s non-inferiority endpoint. The FDA subsequently evaluated a broader clinical package supporting the approved indications.
ZEVTERA was developed by Basilea Pharmaceutica, with Innoviva Specialty Therapeutics acquiring exclusive United States marketing rights in December 2024. The product became commercially available in the United States in 2025. Basilea has subsequently reported hospital formulary wins, repeat orders and reimbursement infrastructure that includes outpatient billing arrangements, although these company-reported access indicators should not be interpreted as evidence of broad market penetration.
That distinction will become increasingly important. Antibiotic launches can secure regulatory approval and formulary access yet still face gradual uptake because clinicians must consider organism susceptibility, infection severity, existing standards of care, local resistance patterns and stewardship policies. ZEVTERA’s commercial test is consequently less about the novelty of its label and more about how often hospitals find a clear role for it within established treatment pathways.
Why could NUZOLVENCE face a very different adoption test after FDA approval?
NUZOLVENCE, or zoliflodacin, separates itself from the other two finalists because it is an oral treatment directed at uncomplicated urogenital gonorrhea rather than a primarily hospital-based intravenous therapy. The FDA approved the drug in December 2025 for adults and pediatric patients aged 12 years and older who weigh at least 35 kilograms and have uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. It is administered as a single oral dose.
The approval was supported by a multinational, randomized, controlled, open-label Phase 3 trial involving 930 participants. Innoviva reported that zoliflodacin demonstrated non-inferiority to ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea in that study. The trial was conducted across sites in Belgium, the Netherlands, South Africa, Thailand and the United States, reflecting the global challenge posed by Neisseria gonorrhoeae and its history of developing resistance to multiple antibacterial classes.
NUZOLVENCE also emerged through an unusual development model involving the Global Antibiotic Research and Development Partnership. That collaboration adds another dimension to the product’s significance because antimicrobial development has long faced an economic tension between the need for new drugs and the public-health objective of using new antibiotics carefully enough to preserve their effectiveness.
Commercially, however, approval is only the beginning. Innoviva said earlier in 2026 that it expected to make NUZOLVENCE available during the second half of the year, either independently or with a commercialization partner. As of the company’s latest second-quarter disclosure, that launch preparation remained part of the near-term portfolio agenda.
The next meaningful evidence for NUZOLVENCE will therefore come not from another award nomination but from its actual rollout, clinician uptake, access arrangements and post-launch susceptibility monitoring.
Does Prix Galien finalist status change the clinical evidence behind these antibiotics?
No award designation changes an FDA-approved indication, adds efficacy data or establishes superiority over competing treatments. Prix Galien recognition is better understood as an external assessment of pharmaceutical innovation among recently approved products. The Galien Foundation’s eligibility framework focuses on FDA-approved products from the preceding five years and its awards are selected through dedicated committees.
That distinction is especially important in antimicrobial medicine. Novel mechanisms and difficult-to-treat pathogens can make new antibiotics scientifically significant, but their clinical value remains tied to the populations, organisms and settings examined in their evidence packages and specified in their labels.
The three Innoviva products illustrate that point clearly. XACDURO has a tightly defined Acinetobacter pneumonia indication. ZEVTERA has three separate approved infection settings with specific age and disease parameters. NUZOLVENCE is approved for uncomplicated urogenital gonorrhea and should not be interpreted as authorization for every manifestation or anatomical site of gonococcal infection.
For clinicians and antimicrobial stewardship teams, those boundaries remain far more consequential than an industry award.
What will determine whether Innoviva converts antimicrobial recognition into durable commercial adoption?
Innoviva now has something many antibiotic developers struggle to build: multiple FDA-approved infectious disease products supported by an operating commercial platform. XACDURO is contributing disclosed revenue, ZEVTERA has progressed into United States commercialization, and NUZOLVENCE is approaching its first real test of market adoption following its late-2025 approval.
The portfolio also highlights one of the paradoxes of antimicrobial innovation. Commercial success cannot simply depend on maximizing drug utilization. Appropriate stewardship requires clinicians to preserve newer antibacterial options and use them where microbiology, susceptibility data and clinical circumstances justify treatment. That can create a very different economic model from chronic therapies where expanding patient volume is generally the central commercial objective.
Prix Galien recognition may strengthen the scientific visibility of Innoviva Specialty Therapeutics, particularly when three products are represented simultaneously. The more consequential milestones, however, will emerge from hospital adoption of XACDURO and ZEVTERA, the rollout of NUZOLVENCE, continued resistance surveillance, access and reimbursement, and evidence that the portfolio can build sustainable utilization without weakening the stewardship principles on which modern antimicrobial treatment depends.
When the 2026 Prix Galien USA winners are announced on October 29, the award result will provide another point of recognition. For Innoviva, the larger question is already underway: whether three differentiated antimicrobial products can be converted from regulatory successes into a durable infectious disease franchise while remaining clinically targeted enough to preserve their value.
